NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

I know all about DCF, but they do not have cash flow and making such predictions before approval is a fun exercise, but not hard data one. Additionally Merck has massive resources to scale, and getting similar resources to NWBO without a sale or large partnership would be a challenge involving substantial changes likely to the capital table that might affect that price per share, which is why generally one uses market cap, and does not push out to share price without laying all those comparative capitalization details out.

I don’t think a large price per share at this moment therefore would be realistic except maybe for private companies where all of this is very controlled and stepped and everyone is in agreement as to what money will go where and how much new value it creates, as is done with private internet related companies before they go public.

Unfortunately this is an OTC public biotech that has had its price boxed in by constant short attacks whenever the price gets away from them for too long. And they have not had resources to deal with that and developing their business as well, so finances are focused on pragmatic details.

Additionally, Keytruda had certain actual approvals for various indications that are not yet a given for DCVax-L, and the pricing and cost structure is different.

Interesting exercise, but without laying it all out, for people to see, I would be highly skeptical of the value of the company currently being $187 per share.

DCF:
https://en.m.wikipedia.org/wiki/Discounted_cash_flow